InZS AssociatesbyPrateek YadavPushing the generics button on the biosimilars contractingUnpacking alliances between biosimilar manufacturers and payers: A deep dive by ZS’s Biosimilars CoEApr 14
Natalie YeadonBiologics and Biosimilars in OncologyWith many patents about to expire in coming years, the field of biologics in oncology is about to change dramatically. Biologics are…Feb 25, 2019
DCVCReimagining biologics: AbCellera and Novartis partner to find new disease treatmentsThe companies are joining forces to find therapeutic antibodies for up to 10 target diseases.Feb 14, 2019Feb 14, 2019
InPatent Attorney and Blockchain Technology Business Lawyer - Rahul DevbyRahul DevLawAsia Publication — Patent Opposition in IndiaJan 20, 2016Jan 20, 2016
InPatent Attorney and Blockchain Technology Business Lawyer - Rahul DevbyRahul DevBioSpectrum Asia — Compulsory License of Bayer’s NexavarJan 20, 2016Jan 20, 2016
InZS AssociatesbyPrateek YadavPushing the generics button on the biosimilars contractingUnpacking alliances between biosimilar manufacturers and payers: A deep dive by ZS’s Biosimilars CoEApr 14
Natalie YeadonBiologics and Biosimilars in OncologyWith many patents about to expire in coming years, the field of biologics in oncology is about to change dramatically. Biologics are…Feb 25, 2019
DCVCReimagining biologics: AbCellera and Novartis partner to find new disease treatmentsThe companies are joining forces to find therapeutic antibodies for up to 10 target diseases.Feb 14, 2019
InPatent Attorney and Blockchain Technology Business Lawyer - Rahul DevbyRahul DevLawAsia Publication — Patent Opposition in IndiaJan 20, 2016
InPatent Attorney and Blockchain Technology Business Lawyer - Rahul DevbyRahul DevBioSpectrum Asia — Compulsory License of Bayer’s NexavarJan 20, 2016
InPatent Attorney and Blockchain Technology Business Lawyer - Rahul DevbyRahul DevBioSpectrum — Regulatory Challenges For APAC Businesses — Biotech in Asia PacificJan 10, 2016
